MDNA Fundamental Analysis - MEDICENNA THERAPEUTICS CORP

Fundamental Rating

Overall MDNA gets a fundamental rating of 2 out of 10. We evaluated MDNA against 24 industry peers in the Biotechnology industry. While MDNA seems to be doing ok healthwise, there are quite some concerns on its profitability. MDNA does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

MDNA had negative earnings in the past year.

MDNA had a negative operating cash flow in the past year.

MDNA had negative earnings in each of the past 5 years.

In the past 5 years MDNA always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -41.59%, MDNA is in the better half of the industry, outperforming 66.67% of the companies in the same industry.

The Return On Equity of MDNA (-61.82%) is better than 79.17% of its industry peers.

		Industry Rank	Sector Rank
ROA	-41.59%
ROE	-61.82%
ROIC	N/A

ROA(3y)-67.42%

ROA(5y)-67.89%

ROE(3y)-195.49%

ROE(5y)-148.03%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MDNA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MDNA has more shares outstanding than it did 1 year ago.

MDNA has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, MDNA has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -1.76, we must say that MDNA is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of MDNA (-1.76) is better than 79.17% of its industry peers.

A Debt/Equity ratio of 0.01 indicates that MDNA is not too dependend on debt financing.

MDNA's Debt to Equity ratio of 0.01 is fine compared to the rest of the industry. MDNA outperforms 79.17% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	-1.76

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

MDNA has a Current Ratio of 6.35. This indicates that MDNA is financially healthy and has no problem in meeting its short term obligations.

MDNA has a Current ratio of 6.35. This is amongst the best in the industry. MDNA outperforms 83.33% of its industry peers.

A Quick Ratio of 6.35 indicates that MDNA has no problem at all paying its short term obligations.

With an excellent Quick ratio value of 6.35, MDNA belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	6.35
Quick Ratio	6.35

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MDNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.33%, which is quite impressive.

EPS 1Y (TTM)58.33%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%110%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MDNA will show a very negative growth in Earnings Per Share. The EPS will decrease by -12.16% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-88.14%

EPS Next 2Y-12.16%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MDNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year MDNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as MDNA's earnings are expected to decrease with -12.16% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-12.16%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MDNA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MEDICENNA THERAPEUTICS CORP

TSX:MDNA (8/8/2025, 7:00:00 PM)

1.19

+0.18 (+17.82%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)06-24 2025-06-24/amc

Earnings (Next)08-07 2025-08-07

Inst Owners6.32%

Inst Owner ChangeN/A

Ins Owners14.2%

Ins Owner ChangeN/A

Market Cap99.22M

Analysts82

Price Target4.09 (243.7%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)64.87%

Min EPS beat(2)-2.94%

Max EPS beat(2)132.68%

EPS beat(4)3

Avg EPS beat(4)41.59%

Min EPS beat(4)-2.94%

Max EPS beat(4)132.68%

EPS beat(8)6

Avg EPS beat(8)-2.84%

EPS beat(12)10

Avg EPS beat(12)11.79%

EPS beat(16)12

Avg EPS beat(16)10.73%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-8.36%

EPS NQ rev (1m)-25%

EPS NQ rev (3m)37.5%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)200%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	5.2
P/tB	5.21
EV/EBITDA	N/A

EPS(TTM)-0.15

EYN/A

EPS(NY)-0.28

Fwd EYN/A

FCF(TTM)-0.2

FCFYN/A

OCF(TTM)-0.2

OCFYN/A

SpS0

BVpS0.23

TBVpS0.23

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-41.59%
ROE	-61.82%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-67.42%

ROA(5y)-67.89%

ROE(3y)-195.49%

ROE(5y)-148.03%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	62.26%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	6.35
Quick Ratio	6.35
Altman-Z	-1.76

F-Score3

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)58.33%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%110%

EPS Next Y-88.14%

EPS Next 2Y-12.16%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-9.25%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-1.63%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-1.43%

OCF growth 3YN/A

OCF growth 5YN/A

MEDICENNA THERAPEUTICS CORP (MDNA.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens